About: SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients
Creator	Buesa, Javier Navarro, David Rodríguez-Díaz, Jesús Albert, Eliseo Blasco, María Francés-Gómez, Clara Geller, Geller, Ron Gimenez, Estela Gozalbo-Rovira, Roberto Latorre, Víctor Marina, Alberto Signes-4 Costa, Jaime
source	MedRxiv
abstract	Background: The involvement of SARS-CoV-2 antibodies in mediating immunopathogenetic events in COVID-19 patients has been suggested. By using several experimental approaches, we investigated the potential association between SARS-CoV-2 IgGs recognizing the spike (S) protein receptor-binding domain (RBD), neutralizing antibodies (NtAb) targeting S, and COVID-19 severity. Patients and Methods: This unicenter, retrospective, observational study included 51 hospitalized patients (24 at the intensive care unit; ICU). A total of 93 sera from these patients collected at different time points from the onset of symptoms were analyzed. SARS-CoV-2 RBD IgGs were quantitated by ELISA and NtAb50 titers were measured in a GFP reporter-based pseudotyped virus platform. Demographic and clinical data, complete blood counts, as well as serum levels of ferritin, Dimer-D, C reactive protein (CRP), lactose dehydrogenase (LDH), and interleukin-6 (IL-6) were retrieved from clinical charts. Results: The overall correlation between levels of both antibody measurements was good (Rho=0.79; P=0<0.001). SARS-CoV-2 RBD IgG and NtAb50 levels in sera collected up to day 30 after the onset of symptoms were comparable between ICU and non-ICU patients (P=>0.1). The percentage of patients who exhibited high NtAb50 titers ([≥]160) was similar (P=0.20) in ICU (79%) and non-ICU (60%) patients. Four ICU patients died; two of these achieved NtAb50 titers [≥]1/160 while the other two exhibited a 1/80 titer. Very weak (Rho=>0.0-<0.2) or weak (Rho=>0.2-<0.4) correlations were observed between anti-RBD IgGs, NtAb50, and serum levels pro-inflammatory biomarkers. Conclusions: The data presented herein do not support an association between SARS-CoV-2 RBD IgG or NtAb50 levels and COVID-19 severity
has issue date	2020-07-24(xsd:dateTime)
bibo:doi	10.1101/2020.07.22.20159673
has license	medrxiv
sha1sum (hex)	8d48f700809c8cbf09d75ef8a80a0d2147218525
schema:url	https://doi.org/10.1101/2020.07.22.20159673
resource representing a document's title	SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 Patients
resource representing a document's body	covid:8d48f700809c8cbf09d75ef8a80a0d2147218525#body_text
is schema:about of	named entity 'ICU' named entity 'weak' named entity 'CRP' named entity 'points' named entity 'RECEPTOR BINDING' named entity 'RESPONSES' named entity 'THESE' named entity '27S' named entity 'IL-6' named entity 'ferritin' named entity 'The levels' named entity 'targeting' named entity 'Patients' named entity 'biomarkers' named entity 'SARS-CoV-2' named entity 'COVID-19' named entity 'biomarkers' named entity 'main point' named entity 'SARS' named entity 'spike protein' named entity 'IL-6' named entity 'SARS-CoV-2' named entity 'antibody response' named entity 'IL-6' named entity 'vesicular stomatitis virus' named entity 'COVID-19' named entity 'RBD' named entity 'IL-6' named entity 'serum' named entity 'titer' named entity 'horseradish peroxidase' named entity 'RBD' named entity 'virus' named entity 'antibody' named entity 'RBD' named entity 'prognosis' named entity 'ICU' named entity 'pro-inflammatory' named entity 'HRP' named entity 'ICU' named entity 'SARS' named entity 'GFP' named entity 'SARS' named entity 'IgG' named entity 'germline' named entity 'RBD' named entity 'bovine serum albumin' named entity 'pseudotyped' named entity 'SARS-CoV-2' named entity 'VSV' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'Dimer' named entity 'SARS-CoV-2' named entity 'urea' named entity 'cytokine storms' named entity 'ICU' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'antibody tests' named entity 'RBD' named entity 'RBD' named entity 'laboratory investigation' named entity 'IgG' named entity 'RBD' named entity 'ICU' named entity 'RBD' named entity 'protein' named entity 'PBS' named entity 'dimer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software